Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Beyond the pump: integrating the heart’s endocrine function into early medical education
Adel, Fadi , Pawlina, Wojciech, Kattil, Punnose , Malsawmzuali, J C , Adel, Fadi W , Kattil, Punnose K , Pawlina, Wojciech

Medical Education Online | July 15, 2026 | Volume: 31 | Issue: 1 | Pages: No page available

10.1080/10872981.2026.2704285 | PMID 42455767 Get It

Limited Agreement Regarding Outpatient Preceptor Behaviors: Observer, Residents, Self
Hidaka, Brandon H., Nordin, Terri, Kolarik, Hannah J., Paulson, Deirdre, Hidaka, Brandon H. , Nordin, Terri , Kolarik, Hannah , Paulson, Deirdre

Family Medicine | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22454/fammed.2026.238874 | PMID 42546324 Get It

Background and Objectives: We developed the Mayo Outpatient Precepting Evaluation Tool (MOPET) to assess and improve clinical teaching for family medicine residents. Given the scheduling challenges of peer evaluation, we sought to improve the MOPET’s usefulness by evaluating the reliability of self- and resident-reported teaching behaviors during clinical precepting compared to peer observation. Methods: Forty-eight half-day sessions in a family medicine residency clinic were assessed with parallel observer, preceptor, and resident MOPET forms. Interrater reliability was calculated using the κ (kappa) statistic. Results: Residents reported that preceptors used 14 of 20 teaching behaviors more often than observers. Observers and preceptors significantly agreed on the use of five teaching behaviors, while residents agreed with observers on two teaching behaviors. Conclusions: Although self-assessment and resident-based feedback of preceptor teaching behavior may improve practicality, they are less reliable compared to direct peer observation with the validated MOPET.
Modifiable Risk Factors and Attributable Ischemic Heart Disease Mortality in US States, 1990-2023
Benziger, Catherine P., Stark, Benjamin A., Johnson, Catherine O., Roth, Gregory A., Collaborators, GBD 2023 US IHD, Abohashem, Shady, Ahmed, Syed Anees, Al-Aly, Ziyad, Alsabri, Mohammed A., Antony, Catherine M., Aravkin, Aleksandr Y., Areda, Demelash, Bell, Michelle L., Brauer, Michael, Chi, Gerald, Criqui, Michael H., Dai, Xiaochen, Doshi, Ojas Prakashbhai, Doshi, Rajkumar Prakashbhai, E’mar, Abdel Rahman, Elhadi, Muhammed, Göbölös, Laszlo, Haile, Demewoz, Hebert, Jeffrey J., Hemmati, Mehdi, Ibrahim, Ramzi, Kankam, Samuel Berchi, Kantar, Rami S., Khubchandani, Jagdish, Kim, Min Seo, Kimokoti, Ruth W., Kisa, Adnan, Kokkorakis, Michail, Kumar, Ashish, Liu, Xuefeng, Lv, Lei, Mahmoudi, Morteza, Manla, Yosef, Martinez-Piedra, Ramon, Marzouk, Sammer, Mensah, George A., Mestrovic, Tomislav, Miller, Ted R., Mokdad, Ali H., Mougin, Vincent, Mustafa, Ahmad, Nassar, Mahmoud, Natto, Zuhair S., Nugen, Fred, Parikh, Romil R., Pasovic, Maja, Patil, Shankargouda, Puvvula, Jagadeesh, Ramasamy, Shakthi Kumaran, Rashid, Ahmed Mustafa, Root, Kevin T., Sawhney, Monika, Schuermans, Art, Shariff, Mariam, Shuval, Kerem, Simegn, Gizeaddis Lamesgin, Singh, Rohit, Stafford, Lauryn K., Taiba, Jabeen, Tanwar, Manoj, Teramoto, Masayuki, Thirunavukkarasu, Sathish, Tran, Thang Huu, Uppal, Dipan, Vinayak, Manish, Yuce, Deniz, Murray, Christopher J. L., Moran, Andrew E., Kimokoti, Ruth W , Liu, Xuefeng , Nassar, Mahmoud , Singh, Rohit , Tanwar, Manoj , Yu, Hairui , Taiba, Jabeen , Benziger, Catherine P. , Stark, Benjamin, Johnson, Catherine O., Roth, Gregory A. , Collaborators, GBD, Abohashem, Shady , Al‐Aly, Ziyad , Antony, Catherine M, Aravkin, Aleksandr Y. , Areda, Demelash, Bräuer, Michael , Chi, Gerald , Criqui, Michael H. , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , E’mar, Abdel Rahman, Elhadi, Muhammed, Göbölös, László , Haile, Demewoz , Hébert, Jeffrey J. , Hemmati, Mehdi , Ibrahim, Ramzi , Kankam, Samuel Berchi , Kantar, Rami S. , Khubchandani, Jagdish , Kısa, Adnan , Kokkorakis, Michail , Lv, Lei , Mahmoudi, Morteza , Manla, Yosef , Martínez, Ramón , Marzouk, Sammer , Mensah, George A. , Meštrović, Tomislav , Miller, Ted R. , Mokdad, Ali H. , Mougin, Vincent , Mustafa, Ahmad , Nassar, Mahmoud, Nugen, Fred , Pasovic, Maja , Puvvula, Jagadeesh , Rashid, Ahmed Mustafa , Root, Kevin T., Sawhney, Monika, Schuermans, Art , Shariff, Mariam , Shuval, Kerem , Simegn, Gizeaddis Lamesgin , Stafford, Lauryn K , Teramoto, Masayuki , Thirunavukkarasu, Sathish, Uppal, Dipan , Vinayak, Manish , Yuce, Deniz, Murray, Christopher J. L., Moran, Andrew Edward

JAMA Cardiology | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2435 | PMID 42455550 Get It

Importance Ischemic heart disease (IHD), the leading cause of death in the US, is predominantly due to modifiable risk factors. Estimates of IHD mortality attributable to risk factors provide evidence for health policy decision-making. Objective To estimate the burden of IHD death attributable to risk factors in the US from 1990-2023. Design, Setting, and Participants The Global Burden of Disease Study 2023 (GBD 2023) used vital records and a broad set of epidemiologic data to estimate IHD death rates, risk factor exposure, and relative risk curves for risk-outcome pairs for 1990-2023 for the general population. Data analysis was performed from October 2024 to December 2025. Exposure Twelve metabolic, behavioral, and environmental risk factors. Main Outcomes and Measures The primary outcomes were IHD death rates per 100 000 persons, counts, and attributable risks from 1990-2023 by age, sex, and US state. Estimates include 95% uncertainty intervals (UI). IHD death rates were estimated using ensemble modeling methods. Risk exposures were estimated using bayesian meta-regression methods. Relative risks were estimated following the Burden of Proof framework. Results In 2023, there were 473 000 IHD deaths (95% UI, 414 000-510 000) in the US, a decrease of 58.7% (95% UI, 56.8%-61.0%) in age-standardized rate since 1990. Between 2010 and 2023, there was a 19.0% decrease (95% UI, 15.0%-22.9%) for males and a 24.5% decrease (95% UI, 20.3%-29.7%) for females in IHD death rates. High systolic blood pressure (SBP), dietary risks, and high low-density lipoprotein cholesterol (LDL-C) were the leading risk factors for IHD deaths in 2023, accounting for 47.2% (95% UI, 36.4%-57.0%), 38.6% (95% UI, 17.2%-56.8%), and 28.5% (95% UI, 19.3%-39.6%) of IHD deaths, respectively. Increased exposure to several risk factors substantially increased their attributable burden for IHD deaths in 2023, with high fasting plasma glucose (FPG) increasing 38.8% (95% UI, 11.5%-81.1%) and high body mass index (BMI) increasing 54.5% (95% UI, 41.8%-66.3%) since 1990. Smoking and particulate matter pollution had the greatest decrease in attributable IHD mortality since 1990, at 33.3% (95% UI, 23.6%-41.7%) and 74.9% (95% UI, 46.7%-88.8%), respectively. Conclusion and Relevance Per the results of this systematic analysis of GBD 2023, a total of 88.7% (95% UI, 83.4%-92.5%) of IHD deaths were attributable to modifiable risk factors in the US in 2023, with high SBP, dietary risks, and high LDL-C being the greatest contributors. High BMI and high FPG showed the largest attribution increases, while exposure to other risks did not increase significantly for the population.
Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning
Park, Jihwan, Fan, Leon, Marzinke, Mark A., Sokoll, Lori J., Muthukumar, Alagarraju, Murphy, Sabina A., Sabatine, Marc S., Gurudu, Rachana, Meeusen, Jeff W., Martin, Seth S., Marzinke, Mark A. , Sokoll, Lori J. , Muthukumar, Alagarraju , Murphy, Sabina A. , Sabatine, Marc S. , Gurudu, Rachana, Meeusen, Jeffrey W. , Martin, Seth S.

JAMA Cardiology | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2314 | PMID 42455545 Get It

Importance Although the Martin-Hopkins equation is widely validated and used to estimate low-density lipoprotein cholesterol (LDL-C) for clinical care, a simplified equation could streamline implementation and enable broader adoption. Objective To develop a simplified machine learning–based alternative to the Martin-Hopkins equation using multivariate adaptive regression splines (LDL-C–MH-MARS) and compare its performance with the Friedewald (LDL-C–F), Sampson–National Institutes of Health (LDL-C–S), Modified Sampson (LDL-C–MS), and Martin-Hopkins (LDL-C–MH) equations. Design, Setting, and Participants The Very Large Database of Lipids is a cross-sectional database of clinical lipid measurements from a population-representative convenience sample of adult and pediatric patients. Lipid measurements were performed by Vertical Auto Profile ultracentrifugation between October 1, 2015, and June 30, 2019. The study included patients with complete lipid panel data who were randomly assigned to a training set and a test set. External validation against preparative ultracentrifugation-based LDL-C measurements was performed in reference laboratory datasets from the Mayo Clinic (broad LDL-C concentrations) and the Further Cardiovascular Outcomes Research With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial (observations from patients with low LDL-C concentrations while taking evolocumab). Study data were analyzed from January to October 2025. Exposures LDL-C–F, LDL-C–S, LDL-C–MS, LDL-C–MH, and LDL-C–MH-MARS equations. Main Outcomes and Measures Accuracy of estimated vs ultracentrifugation-measured LDL-C concentration based on bias, root mean square error (RMSE), and concordance by guideline-based categories. Results The study included 4 939 528 patients (mean [SD] age, 56 [16] years; 2 635 486 female [53%]) with complete lipid panel data who were randomly assigned to a training set (n = 3 292 889) and a test set (n = 1 646 639). LDL-C–MH-MARS equation demonstrated a very low median (IQR) bias of −0.1 (−2.1 to 1.8) mg/dL (to convert to millimoles per liter, multiply by 0.0259), comparable with LDL-C–MH. The median (IQR) difference between the MARS and original Martin-Hopkins equations (ie, LDL-C–MH-MARS – LDL-C–MH) was −0.5 (−1.2 to 0) mg/dL, further suggesting comparability between the 2 methods. The RMSE was smallest for LDL-C–MH-MARS (4.7 mg/dL) and LDL-C–MH (4.9 mg/dL), followed by LDL-C–S (5.8 mg/dL), LDL-C-MS (6.0 mg/dL), and LDL-C–F (7.2 mg/dL). The proportion of patients correctly classified according to clinical categories was nearly identical for LDL-C–MH-MARS (89.7%) and LDL-C–MH (89.6%) but lower for LDL-C–S (86.3%), LDL-C–MS (84.7%), and LDL-C–F (83.1%). The LDL-C–MH-MARS, LDL-C–MH, LDL-C–MS, LDL-C–S, and LDL-C–F equations underestimated LDL-C concentration in 16%, 17%, 28%, 39%, and 60%, respectively, when classifying LDL-C less than 70 mg/dL in patients with triglyceride concentrations of 200 to 399 mg/dL (to convert to millimoles per liter, multiply by 0.0113). The patterns of results were similar in external validation datasets, with the LDL-C–MH-MARS and LDL-C–MH equations demonstrating the highest accuracy. Conclusions and Relevance Study results suggest that the new machine learning–based LDL-C equation provided results comparable with those of the original Martin-Hopkins method while simplifying implementation to a single equation.
Outcomes and Costs After Robotic vs Laparoscopic Complex Elective Cholecystectomy
Caldwell, Katharine E., Threlkeld, Edie, Litrel, Joseph, Brocke, Tiffany, Fields, Ryan C., Panni, Roheena Z., Nguyen, Trang, Leigh, Natasha, Sanford, Dominic E., Caldwell, Katharine E. , Threlkeld, Edie, Litrel, Joseph, Brocke, Tiffany K , Fields, Ryan C., Panni, Roheena Z. , Leigh, Natasha L. , Sanford, Dominic E.

JAMA Surgery | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamasurg.2026.2650 | PMID 42455567 Get It

Importance As the use of robotic cholecystectomy increases, its value remains poorly defined for complex elective cholecystectomy (CEC), where complex gallbladder pathology results in increased technical difficulty. Objective To determine whether a robotic approach is associated with improved clinical outcomes and altered total hospital cost as compared with a laparoscopic approach for patients undergoing CEC. Design, Setting, and Participants This cohort study analyzed data from an academic hepatobiliary referral center for patients who underwent cholecystectomy from August 2018 to August 2024. CEC was defined by preoperative criteria: prior aborted or partial cholecystectomy, presence of a cholecystostomy tube, and/or history of gallbladder perforation or fistula. Exposure Robotic-assisted vs laparoscopic cholecystectomy. Main Outcomes and Measures The primary outcome was a composite of an unplanned postoperative endoscopic retrograde cholangiopancreatography or interventional radiology procedure. Secondary outcomes included operative time, postoperative complications, and operative and total hospital costs. Results A total of 863 patients underwent cholecystectomy and met inclusion criteria; 525 (60.8%) were female and 338 (39.2%) were male, and their median (IQR) age was 61 (45-71) years. Among patients undergoing CEC, the laparoscopic approach was independently associated with an increased need for unplanned endoscopic or percutaneous intervention compared with the robotic group (odds ratio, 4.24; 95% CI, 1.24-14.52; P = .02). There were no significant differences in postoperative outcomes between the laparoscopic and robotic groups in patients undergoing non-CEC. Patients undergoing the laparoscopic approach had significantly reduced operating room costs when compared with patients undergoing a robotic approach in both the CEC ($7720 vs $8936, respectively) and non-CEC groups ($6368 vs $ 8351, respectively). However, there was no difference in the overall total cost of care between laparoscopic CEC and robotic CEC groups ($14 309 vs $14 476, respectively). The overall total cost of care was significantly higher for patients undergoing robotic non-CEC as compared with laparoscopic non-CEC ($11 416 vs $9925, respectively). Conclusions and Relevance This study found that for complex gallbladder disease, robotic cholecystectomy offers a clinical advantage, reducing complications and downstream interventions without increasing the overall costs of care. These findings suggest strategic application of the robotic platform may offer clinical advantages in high-complexity gallbladder surgery, maximizing patient benefit and resource efficiency.
Developmental Control of DNA Damage Responses in α- and β-Cells Shapes the Selective β-Cell Susceptibility in Diabetes
Varghese, Sneha S., Peña, Alessandro Giovanni Hernandez-De La, Wang, Liu, Ruiz, Victor, Tixi, Wilma, Pandey, Aparamita, Anchondo, Laura, Chiu, Amy, Wu, Xiwei, Georgia, Senta K. , Shih, Hung-Ping, Bhattacharya, Supriyo, Dhawan, Sangeeta , Wang, Liu , Wei, Zong , Dhawan, Sangeeta , Varghese, Sneha S., Peña, Alessandro Giovanni Hernandez-De La , Ruiz, Victor, Tixi, Wilma, Pandey, Aparamita, Anchondo, Laura M. , Chiu, Amy, Wu, Xiwei, Georgia, Senta K. , Shih, Hung-Ping, Bhattacharya, Supriyo

Diabetes | July 15, 2026 | Volume: 75 | Issue: 9 | Pages: 1612-1628

10.2337/db25-1027 | PMID 42455072 Get It

Accumulation of DNA damage drives β-cell dysfunction, senescence, and death in type 1 and type 2 diabetes. Although α-cell dysfunction also contributes to disease pathology, α-cells remain remarkably resistant to senescence and increased cell death under diabetogenic stress. The mechanisms underlying these differential responses to diabetogenic stress, particularly differences in their DNA damage vulnerability, remain unclear. We demonstrate that replication introduces a window of genomic vulnerability in both α- and β-cells during neonatal growth, with α-cells exhibiting higher replication rates and DNA damage. We show that neonatal β-cells resolve DNA damage more efficiently during mitosis and favor error-free repair, whereas α-cells compensate for their greater DNA-damage vulnerability through increased cellular turnover. Using mouse models of overnutrition and diabetes, we show that β-cells exhibit greater vulnerability to terminal DNA damage and impaired repair capacity under diabetogenic stress, with compensatory replication amplifying this vulnerability. We demonstrate that developmental and postnatal epigenetic programs shape the differential DNA damage vulnerability of postnatal β- and α-cells. Loss of de novo DNA methyltransferase Dnmt3a in pancreatic progenitors selectively increases the DNA damage vulnerability of β-cells from neonatal growth through adulthood. Complementing this developmental process, enhancer analyses reveal lineage-specific DNA damage response regulatory landscapes that are remodeled in β-cells under metabolic stress. Collectively, our findings uncover novel developmental mechanisms that shape the distinct DNA damage responses of postnatal β- and α-cells during growth and diabetes. Article Highlights Mechanisms underlying the differential susceptibility of pancreatic β- and α-cells to diabetogenic stress remain unclear. We investigated whether replication, repair fidelity, and developmental epigenetic programs determine the vulnerability of postnatal β- and α-cells to DNA damage, a key driver of β-cell failure in diabetes. Replication introduces DNA damage vulnerability in both neonatal β- and α-cells, yet β-cells resolve damage more efficiently. Loss of DNA methyltransferase 3a in pancreatic progenitors selectively heightens β-cell DNA damage vulnerability that persists into adulthood. Moreover, diabetogenic stress preferentially compromises β-cell repair fidelity. These findings reveal how developmental programs shape β-cell resilience and may influence lifelong diabetes risk.
Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome
Gans, Melissa , Wyke, Matthew , Manothummetha, Kasama , Lesmana, Harry , Squire, Jacqueline D. , Schmitt, Erica G. , Ale, Hanadys , Shin, Joyce , Chaimowitz, Natalia , Camacho, Juanita Valdes , Wyke, Matthew , Manothummetha, Kasama , Lesmana, Harry , Squire, Jacqueline , Lopes, Joao Pedro , Schmitt, Erica G , Ale, Hanadys , J Shin, Junghee , Chaimowitz, Natalia , Baloh, Carolyn , Bogunovic, Dusan , Espinosa, Joaquin , Gans, Melissa D.

Journal of Human Immunity | July 15, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20260052 | PMID 42459548 Get It

Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by lifelong immune dysregulation leading to high rates of autoimmune disorders, elevated risk of complications from infections, immune hypersensitivity, and a unique form of immunodeficiency. It is now appreciated that DS shares key hallmarks with interferonopathies, with vast remodeling of all branches of the immune system, hypercytokinemia, and widespread autoantibody production. Here within, we review the existing literature with an emphasis on clinical considerations toward monitoring, management, and therapeutic opportunities. We highlight recent research advances that illuminate diagnostic approaches to evaluate immune dysregulation in DS. We also discuss the evidence supporting specific immunomodulatory strategies that could have multidimensional benefits in this population, including JAK inhibitors, intravenous immunoglobulin, and B cell–depleting agents.
The vascular contribution to dementia: World Stroke Organization scientific statement
Biessels, Geert Jan , Debette, Stephanie, Elahi, Fanny M, Geranmayeh, Fatemeh, Hansra, Gurpreet , Hughes, Timothy M, Ihara, Masafumi, Isaacs, Jeremy, Jokinen, Hanna, Nott, Alexi, Pendlebury, Sarah, Peters, Ruth, Schneider, Julie, Smith, Colin, Vemuri, Prashanthi, Webb, Alastair J.S. , Wilcock, Donna M, Hainsworth, Atticus H. , Hansra, Gurpreet K , Smith, Eric Edward , Wardlaw, Joanna Marguerite , Webb, Alastair Js , Hainsworth, Atticus H , Biessels, Geert Jan , Debette, Stéphanie , Elahi, Fanny M. , Geranmayeh, Fatemeh , Hughes, Timothy M. , Ihara, Masafumi , Isaacs, Jeremy D. , Jokinen, Hanna , Nott, Alexi , Pendlebury, Sarah Tamsin , Peters, Ruth , Schneider, Julie A. , Vemuri, Prashanthi , Wilcock, Donna M.

International Journal of Stroke | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17474930261470506 | PMID 42454751 Get It

Background: Alzheimer’s disease (AD) and cerebrovascular pathology are the two most common causes of dementia, frequently co-occurring in older people. Community-based neuropathology studies indicate that vascular disease accounts for approximately one-third of the population-attributable risk of dementia, controlling for other pathologies (including AD). The proportion with vascular disease as co-pathology is likely to be higher (50–70%). The most common vascular substrate is cerebral small vessel disease, which includes small artery fibrosis (arteriolosclerosis), vascular amyloid deposits (cerebral amyloid angiopathy), and monogenic forms of small vessel disease, the commonest being Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Post-stroke cognitive impairment following both ischemic stroke and intracerebral hemorrhage also contributes. Aims and Methods: In this World Stroke Organization (WSO) scientific statement, we assembled a multi-disciplinary international group of experts to review the vascular contribution to dementia, encompassing both vascular and neurodegenerative dementia. This statement has been reviewed and approved by the WSO executive. Results: We summarize the epidemiology, neuropathology, cognitive profile, clinical impact and management of vascular disease in dementia and discuss the recent VasCog-2-WSO diagnostic criteria. We consider the substantial overlap with clinical stroke and with AD dementia. We catalog transcriptomic and proteomic studies that have revealed novel candidate molecules ( COL4A1/4A2, HTRA1, TRIM47, FOXF2 ) as possible treatment targets. We appraise imaging-based biomarkers relevant to vascular disease and potential biochemical markers (vascular endothelial growth factor-A, placental growth factor, interleukin-6, matrix metalloproteinase-9, cathepsin-B). We highlight the potential for vascular interventions to treat not only vascular dementia but also the vascular component of neurodegenerative dementia. We review recent clinical trials targeting multiple pathways, including nitric oxide signaling, high blood pressure, the GABAergic system, angiogenic activity, microglial inhibition, PDE3 and PDE5 inhibition, as well as dietary supplementation with omega-3 fatty acids, s-equol and vitamin E. Finally, we consider upcoming opportunities and challenges relevant to vascular disease in dementia. Conclusion: The vascular contribution to dementia is i) substantial, ii) increasingly understood at molecular and mechanistic levels, iii) a source of potential treatment opportunities. Data Access Statement: no original data are presented in this document.